Use of estriol for treatment of climacteric osteoporosis

• US 5,614,213 A
• Filed: 08/31/1994
• Issued: 03/25/1997
• Est. Priority Date: 03/21/1992
• Status: Expired due to Term

• Current Assignee: Entec Gesellschaft FUER Endokrinologische Technologie mbH
• Original Assignee: Entec Gesellschaft FUER Endokrinologische Technologie mbH
• Inventors: Ernst, Michael, Dittgen, Michael, Elger, Walter, Schneider, Birgitt, Hubler, Doris, Oettel, Michael
• Primary Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US08/295,723
• Time in Patent Office: 937 Days
• Field of Search: 424/449, 514/969
• US Class Current: 424/449
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has up until now been thought ineffective for the treatment of climacteric osteoporosis, develops strong anti-osteoporotic effectiveness upon continuous transdermal application.

Claims

1. A method of treating climacteric osteoporosis comprising continuously transdermally administering from 5 to 25 mg per day of estriol as the sole active ingredient to a person in need of same for at least 24 hours.

2. The method of claim 1 in which the estriol is administered from a transdermal patch.

3. The method of claim 1 in which the estriol is administered from a transdermal emulsion ointment.

4. The method of claim 2 or 3 in which the transdermal patch or ointment contains 5 to 25 mg of estriol per unit dose.